Drug intelligence / Profile preview

bay-1007626

Development stage: Discontinued
Lead developer: Bayer
Modality: Peptides, Small Molecules
Administration: Intrauterine

Overview

BAY1007626 is a synthetic progestin developed by Bayer for use as an intrauterine system (IUS) for long-acting contraception. It acts as a progesterone receptor agonist, mimicking the effects of natural progesterone to prevent pregnancy. The drug was investigated in clinical trials comparing its pharmacological effects, blood levels, and safety profile to established levonorgestrel-releasing IUS products such as Mirena and Jaydess in healthy premenopausal women. The primary indication was contraception via intrauterine delivery.

Targets

PR (Progesterone receptor)

Beyond the preview

Go deeper on bay-1007626.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bay-1007626.

Explore the full profile